U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 2 Urinary Incontinence, CTCAE

MedGen UID:
281701
•Concept ID:
C1557853
•
Finding
Synonym: CTCAE Grade 2 Incontinence, urinary

Definition

Spontaneous; pads indicated; limiting instrumental ADL [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 2 Urinary Incontinence, CTCAE

Professional guidelines

PubMed

Late adverse events in patients with pelvic cancer after oncologic treatment-intervention and treatment effect.
Iselius S, Knutsen A, Mikiver R, Uppugunduri S
Support Care Cancer 2023 Apr 13;31(5):263. doi: 10.1007/s00520-023-07733-3. PMID: 37055633Free PMC Article
Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: A single-team experience.
Akkary R, Guérin F, Chargari C, Jochault L, Audry G, Pio L, Minard-Colin V, Haie-Meder C, Martelli H
Pediatr Blood Cancer 2022 Aug;69(8):e29532. Epub 2022 Jan 6 doi: 10.1002/pbc.29532. PMID: 35739611
Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
León-Mata J, Domínguez JL, Redorta JP, Sousa González D, Alvarez Casal M, Sousa Escandón A, Piñeiro Vázquez E
Arch Esp Urol 2018 May;71(4):426-437. PMID: 29745932

Recent clinical studies

Etiology

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, O'Callaghan ME
Prostate Cancer Prostatic Dis 2023 Mar;26(1):8-15. Epub 2022 Mar 8 doi: 10.1038/s41391-022-00520-x. PMID: 35260794Free PMC Article
Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
Groen VH, van Schie M, Zuithoff NPA, Monninkhof EM, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, Pos FJ, Smeenk RJ, Haustermans K, Isebaert S, Draulans C, Depuydt T, Verkooijen HM, van der Heide UA, Kerkmeijer LGW
Radiother Oncol 2022 Feb;167:127-132. Epub 2021 Dec 28 doi: 10.1016/j.radonc.2021.12.027. PMID: 34968470
Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis.
Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group
Radiother Oncol 2021 May;158:300-308. Epub 2020 Oct 14 doi: 10.1016/j.radonc.2020.10.003. PMID: 33065183
Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer.
Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K
Radiother Oncol 2018 Jun;127(3):423-430. Epub 2018 May 18 doi: 10.1016/j.radonc.2018.05.002. PMID: 29784450
Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
León-Mata J, Domínguez JL, Redorta JP, Sousa González D, Alvarez Casal M, Sousa Escandón A, Piñeiro Vázquez E
Arch Esp Urol 2018 May;71(4):426-437. PMID: 29745932

Diagnosis

Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience.
Laughlin BS, Narang GL, Cheney SM, Humphreys MR, Vargas CE, Keole SR, Rwigema JM, Schild SE, Wong WW
Cancer Rep (Hoboken) 2023 Jan;6(1):e1672. Epub 2022 Jul 5 doi: 10.1002/cnr2.1672. PMID: 35790091Free PMC Article
Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P, van der Horst C, Kimmig B, Zinsser F, Poppe B, Luetzen U, Juenemann KP, Dunst J, Siebert FA
Brachytherapy 2017 Jan-Feb;16(1):186-192. Epub 2016 Oct 27 doi: 10.1016/j.brachy.2016.09.008. PMID: 28341011

Therapy

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, O'Callaghan ME
Prostate Cancer Prostatic Dis 2023 Mar;26(1):8-15. Epub 2022 Mar 8 doi: 10.1038/s41391-022-00520-x. PMID: 35260794Free PMC Article
Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
Groen VH, van Schie M, Zuithoff NPA, Monninkhof EM, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, Pos FJ, Smeenk RJ, Haustermans K, Isebaert S, Draulans C, Depuydt T, Verkooijen HM, van der Heide UA, Kerkmeijer LGW
Radiother Oncol 2022 Feb;167:127-132. Epub 2021 Dec 28 doi: 10.1016/j.radonc.2021.12.027. PMID: 34968470
Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis.
Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group
Radiother Oncol 2021 May;158:300-308. Epub 2020 Oct 14 doi: 10.1016/j.radonc.2020.10.003. PMID: 33065183
Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer.
Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K
Radiother Oncol 2018 Jun;127(3):423-430. Epub 2018 May 18 doi: 10.1016/j.radonc.2018.05.002. PMID: 29784450
Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer.
León-Mata J, Domínguez JL, Redorta JP, Sousa González D, Alvarez Casal M, Sousa Escandón A, Piñeiro Vázquez E
Arch Esp Urol 2018 May;71(4):426-437. PMID: 29745932

Prognosis

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, O'Callaghan ME
Prostate Cancer Prostatic Dis 2023 Mar;26(1):8-15. Epub 2022 Mar 8 doi: 10.1038/s41391-022-00520-x. PMID: 35260794Free PMC Article
Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis.
Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group
Radiother Oncol 2021 May;158:300-308. Epub 2020 Oct 14 doi: 10.1016/j.radonc.2020.10.003. PMID: 33065183
Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer.
Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K
Radiother Oncol 2018 Jun;127(3):423-430. Epub 2018 May 18 doi: 10.1016/j.radonc.2018.05.002. PMID: 29784450
Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.
Zuber S, Weiß S, Baaske D, Schöpe M, Stevens S, Bodis S, Zwahlen DR
Radiat Oncol 2015 Feb 22;10:49. doi: 10.1186/s13014-015-0349-0. PMID: 25880809Free PMC Article
Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer.
Gómez-Iturriaga Piña A, Crook J, Borg J, Lockwood G, Fleshner N
Urology 2010 Jun;75(6):1412-6. Epub 2009 Dec 29 doi: 10.1016/j.urology.2009.04.101. PMID: 20035986

Clinical prediction guides

Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: Early experience.
Laughlin BS, Narang GL, Cheney SM, Humphreys MR, Vargas CE, Keole SR, Rwigema JM, Schild SE, Wong WW
Cancer Rep (Hoboken) 2023 Jan;6(1):e1672. Epub 2022 Jul 5 doi: 10.1002/cnr2.1672. PMID: 35790091Free PMC Article
Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, O'Callaghan ME
Prostate Cancer Prostatic Dis 2023 Mar;26(1):8-15. Epub 2022 Mar 8 doi: 10.1038/s41391-022-00520-x. PMID: 35260794Free PMC Article
Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
Groen VH, van Schie M, Zuithoff NPA, Monninkhof EM, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, Pos FJ, Smeenk RJ, Haustermans K, Isebaert S, Draulans C, Depuydt T, Verkooijen HM, van der Heide UA, Kerkmeijer LGW
Radiother Oncol 2022 Feb;167:127-132. Epub 2021 Dec 28 doi: 10.1016/j.radonc.2021.12.027. PMID: 34968470
Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis.
Spampinato S, Fokdal LU, Pötter R, Haie-Meder C, Lindegaard JC, Schmid MP, Sturdza A, Jürgenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van der Steen-Banasik E, Van Limbergen E, Sundset M, Westerveld H, Nout RA, Jensen NBK, Kirisits C, Kirchheiner K, Tanderup K; EMBRACE Collaborative Group
Radiother Oncol 2021 May;158:300-308. Epub 2020 Oct 14 doi: 10.1016/j.radonc.2020.10.003. PMID: 33065183
Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.
Zuber S, Weiß S, Baaske D, Schöpe M, Stevens S, Bodis S, Zwahlen DR
Radiat Oncol 2015 Feb 22;10:49. doi: 10.1186/s13014-015-0349-0. PMID: 25880809Free PMC Article

Recent systematic reviews

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, O'Callaghan ME
Prostate Cancer Prostatic Dis 2023 Mar;26(1):8-15. Epub 2022 Mar 8 doi: 10.1038/s41391-022-00520-x. PMID: 35260794Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...